CureDuchenne has announced its enthusiastic support and sponsorship of California Senate bill SB 643, which adds Duchenne muscular dystrophy to California’s Genetically Handicapped Persons Program (GHPP) list of eligible medical conditions. The bill, introduced Feb. 17 by Richard Pan (D) — a pediatrician and state senator representing the…
Parent Project Muscular Dystrophy (PPMD), a nonprofit group dedicated to ending Duchenne muscular dystrophy (DMD), has named the Neuromuscular Research Center at the University of California Davis Department of Pysical Medicine and Rehabilitation a certified Duchenne care center. PPMD’s Certified Duchenne Care Center Program,…
Eighteen-year-old Brandon Martz will travel from Michigan to Washington, D.C., to raise awareness for muscular dystrophy (MD) and see the nation’s capital in one “final Dream trip” with the support of Dream Foundation. Brandon was diagnosed with Duchenne muscular dystrophy (DMD) when he was four and was…
Catabasis Pharmaceuticals is facing challenges in its efforts to develop Edasalonexent (CAT-1004) — an oral drug that targets NF-kB, a protein activated in Duchenne muscular dystrophy (DMD) — to treat the rare degenerative disease. Edasalonexent is being evaluated in MoveDMD, an ongoing Phase 1/2 clinical trial (NCT02439216) consisting of…
A gene therapy approach that Benitec Biopharma is developing for oculopharyngeal muscular dystrophy (OPMD) brought impaired muscle strength in mice back to healthy levels and decreased their muscle fibrosis, or scarring, according to a preclinical trial study. Benitec said its approach could become an effective strategy for treating the rare genetic…
Researchers investigated swallowing dysfunctions in Becker muscular dystrophy (BMD) patients and found they have swallowing problems similar to those observed in patients with Duchenne muscular dystrophy (DMD). These observations are important not only for a better understanding of BMD progression, but also to improve the standard care of these patients. The…
Solid Biosciences of Cambridge, Mass., has completed the initial closing of a $50 million Series C round of financing to advance the company’s clinical portfolio of Duchenne muscular dystrophy (DMD) medications and programs. RA Capital Management and Bain Capital Life Sciences are the principal investors, with input also from RTW Investments, Foresite Capital,…
Surgical treatment of severe spine deformities, or scoliosis, can be a treatment possibility for patients with neuromuscular diseases. A case report titled “Spinal fusion in a patient with Fukuyama congenital muscular dystrophy” was published the journal Brain & Development. It showed that a surgical approach for the treatment of progressive scoliosis improved…
The nonprofit CureDuchenne organization has changed its website to better reflect its mission of improving the lives of people with Duchenne muscular dystrophy (DMD). CureDuchenne and the DMD community have taken heart from two recent Federal Drug Administration approvals. The initial one, in September 2016, was for the first-ever drug…
Hundreds seeking a cure for Duchenne muscular dystrophy will join April 8 at the University of Texas (UT) Golf Club for the Champions to CureDuchenne gala, now in its eighth year. The event, hosted by Quan Cosby, former wide receiver on the UT football team, and presented by…
Get regular updates to your inbox.